Dr. Sven K. Weber Appointed CEO of BRAIN Biotech AG, Succeeding Adriaan Moelker
Key Insights
Dr. Sven K. Weber will assume the role of CEO at BRAIN Biotech AG (search) effective October 1, 2026, succeeding Adriaan Moelker who is retiring after six years of leadership.
Dr. Weber brings extensive experience from BASF Group (search), where he most recently served as Vice President of the global enzyme business, driving innovation-led profitable growth.
Outgoing CEO Adriaan Moelker repositioned BRAIN Biotech as an integrated manufacturing company in the enzyme sector and will remain as a senior advisor until January 2027.
ZWINGENBERG, Germany — The Supervisory Board of BRAIN Biotech AG (search) has appointed Dr. Sven K. Weber as the company's new Chief Executive Officer, effective October 1, 2026. Dr. Weber will succeed Adriaan Moelker, who has led the enzyme-focused biotechnology firm for the past six years and will retire following the completion of his contract term on September 30, 2026.
Dr. Weber, 44, joins BRAIN Biotech from the BASF Group (search), where he has held various leadership positions since 2011. Most recently, he served as Vice President responsible for BASF Group's global enzyme business within the Global Business Unit Feed Enzymes & Feed Performance Ingredients. In this capacity, he consistently aligned the business toward innovation-driven, profitable growth and significantly increased both revenue and earnings.
Prior to his role in the enzyme business, Dr. Weber served as Global Segment Director for the global automotive OEM business at Chemetall GmbH and headed contract research at hte GmbH in Heidelberg, a leading provider of high-throughput solutions for R&D workflows. He began his professional career at the Merck Group (search) in Darmstadt. Dr. Weber holds a diploma in chemistry and earned his doctorate from the University of Heidelberg, and completed an executive program in general management at the SGMI Management Institute in St. Gallen, focusing on strategy, corporate management, and finance.
Leadership Transition and Strategic Continuity
Adriaan Moelker, who has served as CEO since 2020, will step down from the Executive Board on September 30, 2026, and will continue to serve BRAIN Biotech as a senior advisor until the end of his contract term in January 2027. Under Moelker's leadership, BRAIN Biotech was repositioned as an integrated manufacturing company in the enzyme sector, and the company successfully monetized projects from the BRAINBioIncubator.
Dr. Michael Majerus, Chairman of the Supervisory Board of BRAIN Biotech AG (search), stated: "Over the past six years, Adriaan Moelker has repositioned BRAIN Biotech AG as an integrated manufacturing company in the enzyme sector and has successfully monetized projects from the BRAINBioIncubator. For this, I would like to express my sincere thanks to Adriaan on behalf of the entire Supervisory Board."
Majerus added: "I am now very pleased that, with Dr. Weber, we have been able to bring on board an internationally experienced leader with proven expertise in the industrial enzyme business. He will continue implementing the company's strategic direction, tap into additional growth potential, and accelerate its operational implementation."
Vision for Growth
Dr. Weber expressed his commitment to building on the company's existing strengths. "BRAIN Biotech has a strong technological foundation and excellent scientific expertise. Together with the group's employees I intend to build on this in order to accelerate growth, sustainably strengthen profitability, and bring innovative products to market more quickly for the benefit of our customers," he said.
Dr. Weber further outlined his strategic ambition: "My goal is to develop BRAIN into a leading provider of specialty enzymes in selected application areas and to tap into additional growth potential through the BRAINBioIncubator."
Company Profile
The BRAIN Biotech Group specializes in researching, developing, and producing specialty enzymes, with a focus on the food and life sciences industries. The group also develops microbial production strains and scalable bioprocesses for the economic production of specialty enzymes and other proteins, and offers customized biological solutions for more sustainable products and efficient processes.
BRAIN Biotech AG (search), the parent company, operates through two business segments: BRAINBiocatalysts, which encompasses the development, production, and distribution of specialty enzymes, microorganisms, and ingredients; and BRAINBioIncubator, focused on research-intensive development projects and pharmaceuticals. The company operates its own fermentation facilities in the UK with additional production sites in continental Europe and the US. In the 2024/25 fiscal year, the group generated revenue of €49.6 million with approximately 280 employees. BRAIN Biotech AG has been listed on the Frankfurt Stock Exchange since February 9, 2016, under the ticker symbol BNN.